NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 312 filers reported holding NOVOCURE LTD in Q4 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,461 | -99.8% | 462 | -99.4% | 0.00% | -99.7% |
| Q2 2023 | $3,194,172 | +0.8% | 76,968 | +46.1% | 0.34% | -8.4% |
| Q1 2023 | $3,167,514 | -14.2% | 52,669 | +4.6% | 0.37% | -18.5% |
| Q4 2022 | $3,693,466 | +28311.3% | 50,354 | +29346.8% | 0.46% | +22650.0% |
| Q3 2022 | $13,000 | +333.3% | 171 | +271.7% | 0.00% | – |
| Q2 2022 | $3,000 | -25.0% | 46 | -9.8% | 0.00% | -100.0% |
| Q1 2022 | $4,000 | +300.0% | 51 | +410.0% | 0.00% | – |
| Q4 2021 | $1,000 | -90.0% | 10 | -88.9% | 0.00% | -100.0% |
| Q3 2021 | $10,000 | -68.8% | 90 | -37.1% | 0.00% | -57.1% |
| Q2 2021 | $32,000 | +88.2% | 143 | +10.0% | 0.01% | +75.0% |
| Q1 2021 | $17,000 | -5.6% | 130 | +23.8% | 0.00% | 0.0% |
| Q4 2020 | $18,000 | +63.6% | 105 | +5.0% | 0.00% | +33.3% |
| Q3 2020 | $11,000 | +175.0% | 100 | +33.3% | 0.00% | +200.0% |
| Q2 2020 | $4,000 | – | 75 | – | 0.00% | – |
| Q4 2018 | $0 | – | 0 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $26,344,000 | 8.01% |
| HARTLINE INVESTMENT CORP/ | 318,109 | $23,884,000 | 3.27% |
| Deep Track Capital, LP | 550,000 | $41,294,000 | 2.92% |
| MORGAN JESS S & CO INC | 43,975 | $3,302,000 | 2.03% |
| Taylor Frigon Capital Management LLC | 46,376 | $3,482,000 | 1.09% |
| Darsana Capital Partners LP | 258,937 | $19,441,000 | 0.90% |
| Private Harbour Investment Management & Counsel, LLC | 13,562 | $1,018,000 | 0.81% |
| Rhenman & Partners Asset Management AB | 120,387 | $9,610,000 | 0.64% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $751,000 | 0.50% |
| Baillie Gifford | 9,615,168 | $721,906,000 | 0.40% |